Developing game changing treatments and cell therapies for severe diseases
We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.
“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”
Professor Ann Logan,
Scientific Director, Neuregenix Ltd.
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
ILB – A game changer in Glaucoma
Anders Kristensson appointed CEO of TikoMed
TIKOMED WILL SPEAK AT BOSTON BIOTECH CELL AND GENE THERAPY CEO MEETING